KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) Equity Ratio (2016 - 2025)

Arbutus Biopharma's Equity Ratio history spans 15 years, with the latest figure at 0.79 for Q3 2025.

  • For Q3 2025, Equity Ratio rose 4.08% year-over-year to 0.79; the TTM value through Sep 2025 reached 0.79, up 4.08%, while the annual FY2024 figure was 0.74, 0.69% up from the prior year.
  • Equity Ratio for Q3 2025 was 0.79 at Arbutus Biopharma, down from 0.8 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.83 in Q4 2021 and bottomed at 0.68 in Q1 2025.
  • The 5-year median for Equity Ratio is 0.75 (2023), against an average of 0.75.
  • The largest annual shift saw Equity Ratio grew 11.4% in 2021 before it dropped 15.49% in 2022.
  • A 5-year view of Equity Ratio shows it stood at 0.83 in 2021, then decreased by 15.49% to 0.7 in 2022, then increased by 4.84% to 0.73 in 2023, then increased by 0.69% to 0.74 in 2024, then grew by 7.15% to 0.79 in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Equity Ratio are 0.79 (Q3 2025), 0.8 (Q2 2025), and 0.68 (Q1 2025).